Melanoma antibody

Catalog No. ABIN6252231

Product Details anti-Melanoma Antibody

Target: Melanoma

Reactivity: Human, Dog, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: This Melanoma antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Western Blotting (WB)

Purification: Protein G affinity chromatography

Immunogen: Melanocyte antigen was used as the immunogen for the Melanoma antibody PNL2.

Clone: PNL2

Isotype: IgG1

Application Details

Application Notes: Immunofluorescence: 0.5-1 μg/mL

Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)

Prediluted format: incubate for 30 min at RT (2)

Optimal dilution of the Melanoma antibody PNL2 should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: PBS with 0.1 mg/mL BSA and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot and Store at -20C. Avoid freez-thaw cycles.

Target Details for Melanoma

Target: Melanoma

Abstract: Melanoma Products

Background: Anti-PNL2 is a novel monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope id not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87 % ), as opposed to 76 % for anti-HMB45 and 82 % for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angio-myolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.